Naito Atsushi, Imasato Mitsunobu, Iwamoto Kazuya, Takeda Mitsunobu, Hyuga Satoshi, Ohashi Tomofumi, Nakahara Yujiro, Furukawa Kenta, Moon Jeongho, Asaoka Tadafumi, Mizushima Tsunekazu
Dept. of Gastroenterological Surgery, Osaka Police Hospital.
Gan To Kagaku Ryoho. 2023 Jan;50(1):113-115.
FOLFIRI plus ramucirumab(RAM)therapy has been reported to be effective and safe in the RAISE trial as second-line treatment for unresectable colorectal cancer. It is hypothesized that RAM may be effective in patients with PD treated with FOLFIRI plus bevacizumab(Bev)due to different mechanism of action from that of Bev, which is also an angiogenesis inhibitor. From January 2017 to December 2021, we conducted a retrospective study of 6 patients who had PD with 5-FU, oxaliplatin, irinotecan, or Bev as first or second-line treatment at our institution and who received FOLFIRI plus RAM in later line treatment. The 6 cases consisted of 3 patients in the third-line treatment, 1 patient in the fourth-line treatment, and 2 patients in the sixth-line treatment. The anti-tumor effect was PD in all cases in the third-line and fourth-line treatment, but the 2 patients of sixth-line treatment were controlled diseases.
在RAISE试验中，FOLFIRI联合雷莫西尤单抗（RAM）疗法作为不可切除结直肠癌的二线治疗已被报道有效且安全。据推测，由于RAM与同为血管生成抑制剂的贝伐单抗（Bev）作用机制不同，RAM可能对接受FOLFIRI联合贝伐单抗（Bev）治疗后疾病进展（PD）的患者有效。2017年1月至2021年12月，我们对6例在我院接受过一线或二线5-氟尿嘧啶、奥沙利铂、伊立替康或贝伐单抗治疗后疾病进展（PD）且在后续治疗中接受FOLFIRI联合RAM治疗的患者进行了一项回顾性研究。这6例患者包括3例三线治疗患者、1例四线治疗患者和2例六线治疗患者。三线和四线治疗的所有病例抗肿瘤效果均为疾病进展（PD），但六线治疗的2例患者疾病得到控制。
